216 related articles for article (PubMed ID: 16881055)
1. Ocular phenotype in a mouse gene knockout model for infantile neuronal ceroid lipofuscinosis.
Lei B; Tullis GE; Kirk MD; Zhang K; Katz ML
J Neurosci Res; 2006 Oct; 84(5):1139-49. PubMed ID: 16881055
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic characterization of a mouse model of juvenile neuronal ceroid lipofuscinosis.
Katz ML; Johnson GS; Tullis GE; Lei B
Neurobiol Dis; 2008 Feb; 29(2):242-53. PubMed ID: 17962032
[TBL] [Abstract][Full Text] [Related]
3. Behavioral assessment in mouse models of neuronal ceroid lipofuscinosis using a light-cued T-maze.
Wendt KD; Lei B; Schachtman TR; Tullis GE; Ibe ME; Katz ML
Behav Brain Res; 2005 Jun; 161(2):175-82. PubMed ID: 15885820
[TBL] [Abstract][Full Text] [Related]
4. Pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis.
Whiting RE; Narfström K; Yao G; Pearce JW; Coates JR; Castaner LJ; Katz ML
Exp Eye Res; 2013 Nov; 116():402-10. PubMed ID: 24135299
[TBL] [Abstract][Full Text] [Related]
5. The novel Cln1(R151X) mouse model of infantile neuronal ceroid lipofuscinosis (INCL) for testing nonsense suppression therapy.
Miller JN; Kovács AD; Pearce DA
Hum Mol Genet; 2015 Jan; 24(1):185-96. PubMed ID: 25205113
[TBL] [Abstract][Full Text] [Related]
6. Multifocal retinopathy in Dachshunds with CLN2 neuronal ceroid lipofuscinosis.
Whiting RE; Pearce JW; Castaner LJ; Jensen CA; Katz RJ; Gilliam DH; Katz ML
Exp Eye Res; 2015 May; 134():123-32. PubMed ID: 25697710
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal enzyme replacement therapy improves motor function and survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis.
Lu JY; Nelvagal HR; Wang L; Birnbaum SG; Cooper JD; Hofmann SL
Mol Genet Metab; 2015; 116(1-2):98-105. PubMed ID: 25982063
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive assessment of retinal alterations in mouse models of infantile and juvenile neuronal ceroid lipofuscinosis by spectral domain optical coherence tomography.
Groh J; Stadler D; Buttmann M; Martini R
Acta Neuropathol Commun; 2014 May; 2():54. PubMed ID: 24887158
[TBL] [Abstract][Full Text] [Related]
9. Retinal pathology and function in a Cln3 knockout mouse model of juvenile Neuronal Ceroid Lipofuscinosis (batten disease).
Seigel GM; Lotery A; Kummer A; Bernard DJ; Greene ND; Turmaine M; Derksen T; Nussbaum RL; Davidson B; Wagner J; Mitchison HM
Mol Cell Neurosci; 2002 Apr; 19(4):515-27. PubMed ID: 11988019
[TBL] [Abstract][Full Text] [Related]
10. Gene disruption of Mfsd8 in mice provides the first animal model for CLN7 disease.
Damme M; Brandenstein L; Fehr S; Jankowiak W; Bartsch U; Schweizer M; Hermans-Borgmeyer I; Storch S
Neurobiol Dis; 2014 May; 65():12-24. PubMed ID: 24423645
[TBL] [Abstract][Full Text] [Related]
11. Retinal degeneration in motor neuron degeneration: a mouse model of ceroid lipofuscinosis.
Chang B; Bronson RT; Hawes NL; Roderick TH; Peng C; Hageman GS; Heckenlively JR
Invest Ophthalmol Vis Sci; 1994 Mar; 35(3):1071-6. PubMed ID: 8125718
[TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis.
Whiting RE; Narfström K; Yao G; Pearce JW; Coates JR; Castaner LJ; Jensen CA; Dougherty BN; Vuillemenot BR; Kennedy D; O'Neill CA; Katz ML
Exp Eye Res; 2014 Aug; 125():164-72. PubMed ID: 24954537
[TBL] [Abstract][Full Text] [Related]
13. Electroretinographic and clinicopathologic correlations of retinal dysfunction in infantile neuronal ceroid lipofuscinosis (infantile Batten disease).
Weleber RG; Gupta N; Trzupek KM; Wepner MS; Kurz DE; Milam AH
Mol Genet Metab; 2004; 83(1-2):128-37. PubMed ID: 15464427
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease).
Hawkins-Salsbury JA; Cooper JD; Sands MS
Biochim Biophys Acta; 2013 Nov; 1832(11):1906-9. PubMed ID: 23747979
[TBL] [Abstract][Full Text] [Related]
15. Visual system pathology in a canine model of CLN5 neuronal ceroid lipofuscinosis.
Kick GR; Meiman EJ; Sabol JC; Whiting REH; Ota-Kuroki J; Castaner LJ; Jensen CA; Katz ML
Exp Eye Res; 2021 Sep; 210():108686. PubMed ID: 34216614
[TBL] [Abstract][Full Text] [Related]
16. Mice with Ppt1Deltaex4 mutation replicate the INCL phenotype and show an inflammation-associated loss of interneurons.
Jalanko A; Vesa J; Manninen T; von Schantz C; Minye H; Fabritius AL; Salonen T; Rapola J; Gentile M; Kopra O; Peltonen L
Neurobiol Dis; 2005 Feb; 18(1):226-41. PubMed ID: 15649713
[TBL] [Abstract][Full Text] [Related]
17. Exacerbated neuronal ceroid lipofuscinosis phenotype in Cln1/5 double-knockout mice.
Blom T; Schmiedt ML; Wong AM; Kyttälä A; Soronen J; Jauhiainen M; Tyynelä J; Cooper JD; Jalanko A
Dis Model Mech; 2013 Mar; 6(2):342-57. PubMed ID: 23065637
[TBL] [Abstract][Full Text] [Related]
18. Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice.
Gupta P; Soyombo AA; Atashband A; Wisniewski KE; Shelton JM; Richardson JA; Hammer RE; Hofmann SL
Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13566-71. PubMed ID: 11717424
[TBL] [Abstract][Full Text] [Related]
19. Dietary carnitine supplements slow disease progression in a putative mouse model for hereditary ceroid-lipofuscinosis.
Katz ML; Rice LM; Gao CL
J Neurosci Res; 1997 Oct; 50(1):123-32. PubMed ID: 9379488
[TBL] [Abstract][Full Text] [Related]
20. Mouse models of neuronal ceroid lipofuscinoses: useful pre-clinical tools to delineate disease pathophysiology and validate therapeutics.
Shacka JJ
Brain Res Bull; 2012 May; 88(1):43-57. PubMed ID: 22502604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
